Myhibbin Suspension
NDC Package 24338-018-01
Package Information
Myhibbin (mycophenolate mofetil) suspension is mycophenolate is used in combination with other medications to keep your body from attacking and rejecting your transplanted organ (such as kidney, liver, heart). This formulation utilizes a suspension delivery system. Marketed by Azurity Pharmaceuticals, Inc., this product is identified by NDC 24338-018 and is authorized under FDA application NDA216482.
Identification & Billing
- RxCUI: 2684851 - Myhibbin 200 MG in 1 mL Oral Suspension
- RxCUI: 2684851 - mycophenolate mofetil 200 MG/ML Oral Suspension [Myhibbin]
- RxCUI: 2684851 - Myhibbin 200 MG per 1 ML Oral Suspension
- RxCUI: 2684851 - Myhibbin 200 MG/ML Oral Suspension
- RxCUI: 311880 - mycophenolate mofetil 200 MG in 1 mL Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 24338 - Azurity Pharmaceuticals, Inc.
- 24338-018 - Myhibbin
- 24338-018-01 - 1 BOTTLE, PLASTIC in 1 CARTON / 175 mL in 1 BOTTLE, PLASTIC
- 24338-018 - Myhibbin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 24338-018-01 identifies a specific commercial package of 1 bottle, plastic in 1 carton / 175 ml in 1 bottle, plastic of Myhibbin, a human prescription drug labeled by Azurity Pharmaceuticals, Inc.. This suspension is formulated for oral use and contains mycophenolate mofetil as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Azurity Pharmaceuticals, Inc. on June 10, 2024. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Mycophenolate is used in combination with other medications to keep your body from attacking and rejecting your transplanted organ (such as kidney, liver, heart). It belongs to a class of medications called immunosuppressants. It works by weakening your body's defense system (immune system) to help your body accept the new organ as if it were your own.
How is this Azurity Pharmaceuticals, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 24338001801. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
